955results about How to "Improved prognosis" patented technology

Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and / or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compositions, and methods for treating a mammal with vascular disease such as restenosis, artherosclerosis or other types of vessel obstructions are disclosed.

System and method for developing a treatment plan for achieving a treatment goal including creating a virtual model of a dental patient's dentition; transforming the virtual model of the dentition using virtual prosthodontics to facilitate achievement of the treatment goal; transforming the virtual model of the dentition using virtual orthodontics to facilitate achievement of the treatment goal; iterating on the transforming steps until substantially achieving the treatment goal; and generating an orthodontic treatment plan and a prosthodontic treatment plan based upon the substantially achieved treatment goal

A method and system for morphology based mitosis identification and classification of digital images. Luminance parameters such as intensity, etc. from a digital image of a biological sample (e.g., tissue cells) to which a chemical compound (e.g., a marker dye) has been applied are analyzed and corrected if necessary. Morphological parameters (e.g., size, elongation ratio, parallelism, boundary roughness, convex hull shape, etc.) from individual components within the biological sample are analyzed. A medical conclusion (e.g., type and count of mitotic cells) or a life science and biotechnology experiment conclusion is determined from the analyzed luminance and morphological parameters. The method and system may be used to develop applications for automatically obtaining a medical diagnosis (e.g., a carcinoma diagnosis).

Methods and compositions for evaluating the prognosis of a breast cancer patient, particularly an early-stage breast cancer patient, are provided. The methods of the invention comprise detecting expression of at least one, more particularly at least two, biomarker(s) in a body sample, wherein overexpression of the biomarker or a combination of biomarkers is indicative of breast cancer prognosis. In some embodiments, the body sample is a breast tissue sample, particularly a primary breast tumor sample. The biomarkers of the invention are proteins and / or genes whose overexpression is indicative of either a good or bad cancer prognosis. Biomarkers of interest include proteins and genes involved in cell cycle regulation, DNA replication, transcription, signal transduction, cell proliferation, invasion, proteolysis, or metastasis. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques.

Methods are disclosed for the capture, detection, separation, isolation and quantification of contaminants in a starting material. Also disclosed are competitive assay methods for the detection and quantification of contaminants in a starting material. Kits for use with the method are disclosed as well. A system for capturing, separating and / or concentrating contaminants from a material is also presented. The system captures, separates and / or concentrates contaminants such as bacteria, viruses, other microorganisms, and / or larger items, such as insects, from a variety of materials, such as food, and environmental and clinical materials. In general, the system uses a rotating magnetic field to mix the material with magnetic particles to capture the target contaminants, and a fixed magnetic field to separate and concentrate the captured target contaminants.

Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and / or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compositions, and methods for treating a mammal with vascular disease such as restenosis, artherosclerosis or other types of vessel obstructions are disclosed.

Methods are provided for detecting, separating, isolating and quantifying contaminants in starting materials by separating the contaminant from the starting material using a bead coupled to an affinity moiety and quantum dot-labeling the contaminant. The contaminant is detected by the characteristic emission spectrum of the quantum dot. Also, competitive binding methods are provided wherein the starting material and a control material are contacted with a quantum dot coupled to an affinity moiety capable of binding the contaminant and a competitor complex. A decrease in the intensity of the characteristic emission spectrum of the quantum dot associated with the competitor complex from the starting material as compared to that of the control material is indicative of the presence of the contaminant in the starting material.

A system and method is provided for fault detection in a turbine engine. The fault detection system and method uses discrete event system modeling to provide improved fault diagnosis and prognosis. The fault detection system and method receives sensor taken at multiple dynamic events occurring in different time windows. An event determination mechanism evaluates the received sensor data to determine if specified events have occurred. Indications of the occurrence of specified events are then passed to a discrete event system model. The discrete event system model analyzes the timing and sequencing of the event occurrences to determine if a fault has occurred. This method does not require a detailed modeling of the system, and thus can be applied to complex systems such as turbine engines.

The present invention relates to methods for the diagnosis and evaluation of subclinical atherosclerosis. In particular, patient test samples are analyzed for the presence and amount of one or more natriuretic peptides. A variety of additional markers are disclosed for assembling a panel of markers for such diagnosis and evaluation.

The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., lung cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Ephr. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of lung cell lines to the compounds. The expression level of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., lung cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.

The present invention relates to methods of detection, prognosis and treatment of breast cancer using a plurality genes or gene products present in normal and neoplastic cells, tissues and bodily fluids. Gene products relate to compositions comprising the nucleic acids, polypeptides, antibodies, post translational modifications (PTMs), variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. Additional uses include identifying, monitoring, staging, imaging and treating cancer and non-cancerous disease states in breast as well as determining the effectiveness of therapies alone or in combination for an individual. Therapies include gene therapy, therapeutic molecules including but not limited to antibodies, small molecules and antisense molecules.

A method of using an integrated intraluminal imaging system includes an optical coherence tomography interferometer (OCT), an ultrasound subsystem (US) and a phase resolved acoustic radiation force optical coherence elastography subsystem (PR-RAF-OCE). The steps include performing OCT to generate a returned optical signal, performing US imaging to generate a returned ultrasound signal, performing PR-ARF-OCE to generate a returned PR-ARF-OCE signal by generating a amplitude modulated ultrasound beam or chirped amplitude modulated ultrasound beam to frequency sweep the acoustic radiation force, measuring the ARF induced tissue displacement using phase resolved OCT method, and the frequency dependence of the PR-ARF-OCE signal, processing the returned optical signal, the returned ultrasound signal and the measured frequency dependence of the returned PR-ARF-OCE optical coherence elastographic signal to quantitatively measure the mechanical properties of the identified tissues with both spectral and spatial resolution using enhanced materials response at mechanically resonant frequencies to distinguish tissues with varying stiffness, to identify tissues with different biomechanical properties and to measure structural and mechanical properties simultaneously.